Manali Kamdar, MD, on the Curative Potential of Liso-Cel in Third-Line R/R LBCL
The clinical director of lymphoma services at the University of Colorado discussed 5-year follow-up data from the TRANSCEND-NHL-001 clinical trial.
“This goes on to show that liso-cel demonstrates a curative potential of 38% at the 5-year mark in the patients who have received it in the third-line setting.”
Bristol Myers Squibb’s lisocabtagene maraleucel (liso-cel, marketed as Breyanzi), an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy, was approved by the FDA for the treatment of third-line relapsed/refractory (r/r) large B-cell lymphoma (LBCL) based on results from the TRANSCEND-NHL-001 clinical trial (NCT02631044). Following the approval, the study continued to collect data on the treated patients, before it finally completed in 2024. At the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 7-10, 2024, in San Diego, California, Jeremy S. Abramson, MD, the director of the Lymphoma Program and the Jon and Jo Ann Hagler Chair in Lymphoma at the Massachusetts General Hospital Cancer Center, presented 5-year survival data from patients treated in the LBCL cohort in TRANSCEND-NHL-001.
Following the close of the conference, CGTLive® got in touch with Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, to learn more about the data Abramson presented and its implications. Kamdar went over the key results, highlighting that the median overall survival at 5 years was 27.5 months with an estimated overall survival rate at 5 years of 38%. She also pointed out that that the median disease-specific survival at 5 years was 68 months and that the estimated disease-specific survival rate at 5 years was 52%. Kamdar emphasized that these results support the curative potential of liso-cel for r/r LBCL in the third-line setting, having noted that patients with diffuse LBCL who remain in remission at 5 years of follow-up are typically considered to have been cured. Kamdar also discussed the 5-year safety data, pointing out that there were no new toxicity signals since the 2-year follow-up.
REFERENCE
1. Abramson JS, Palomba ML, Gordon LI, et al. Five-year survival of patients (pts) from Transcend NHL 001 (TRANSCEND) supports curative potential of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (r/r) large B-cell lymphoma (LBCL). Presented at: ASH 2024 Annual Meeting. December 7-10, 2024; San Diego, CA. Abstract 3125
Transplant Eligibility Versus CAR-T Eligibility
January 16th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.
Sequencing of Treatment in Third-Line R/R LBCL
January 15th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.
